海能未来技术集团股份有限公司（以下简称"公司"）近日收到国家知识产 权局核发的《发明专利证书》一项，具体情况如下： 发明名称：坩埚自动清理装置及具有其的元素分析仪 专利号：ZL 2020 1 1313151.4 专利申请日：2020 年 11 月 20 日 证券代码：430476 证券简称：海能技术 公告编号：2025-072 海能未来技术集团股份有限公司 关于公司获得发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、基本情况 上述发明专利主要应用于公司的有机元素分析仪产品。公司的有机元素分析 系列产品可广泛应用于新药研发、医药原料、医药中间体的化合物元素组成测定； 医用敷料中的胶原蛋白、生物制药中的疫苗及其辅料的蛋自质含量检测；中药二 氧化硫残留量检测；粮食油脂、乳制品、宠物食品、畜牧饲料、预制菜的营养与 安全检测；高分子材料、新材料研发中元素含量测定；土壤、肥料、农作物中总 氮含量测定；污水、废弃物、沉积物中有机元素含量测定；柴油车尾气处理液、 石油、煤炭中有机元素含量测定等领 ...

Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook on its future performance [3][5]. Core Viewpoints - The company is positioned as a "small giant" in the scientific instruments sector, with a comprehensive product lineup and a strong focus on high-end analytical instruments. It aims to reduce reliance on upstream supply chains through vertical integration [1][3]. - The company has shown significant recovery in its performance, with a notable reduction in net losses and a year-over-year revenue growth of 38% in Q1 2025 [1][3]. - The chromatography market in China is expanding rapidly, with a projected growth from 9.2 billion to 16 billion yuan from 2019 to 2024, and the company is well-positioned to capitalize on this trend through its innovative products [2][3]. Summary by Sections 1. Company Overview - Established in 2006, the company focuses on scientific instruments, offering a wide range of products including organic element analysis, sample preparation, chromatography, and general instruments [1][14]. - The company has received multiple certifications and accolades, including being recognized as a "small giant" enterprise and a high-tech enterprise [14][15]. 2. Market Position and Product Strength - The company leads in the organic element analysis sector, with successful products like the Kjeldahl nitrogen analyzer and microwave digestion systems, which have seen significant sales growth in various industries [1][2]. - The sample preparation segment has also performed well, particularly in the lithium battery and petrochemical sectors, with notable clients including BYD and PetroChina [1][2]. 3. Chromatography Market Potential - The chromatography market is characterized by high import rates, with only 16.4% domestic production in 2024, indicating substantial room for domestic players to grow [2][3]. - The company is expanding its product offerings in this area with the "Wukong" high-efficiency liquid chromatography and "GAS" gas chromatography-ion mobility spectrometry instruments, which are gaining acceptance in various industries [2][3]. 4. Financial Projections - The company is expected to achieve revenues of 3.7 billion, 4.5 billion, and 5.4 billion yuan from 2025 to 2027, with corresponding net profits of 0.5 billion, 0.7 billion, and 1.0 billion yuan [3][4]. - The projected earnings per share (EPS) for the same period are 0.54, 0.82, and 1.13 yuan, reflecting a positive growth trajectory [3][4]. 5. Investment and Growth Strategy - The company employs a multi-brand strategy to enhance brand recognition and market penetration across various product lines, which supports its revenue growth and cash flow stability [29][35]. - It has engaged in strategic acquisitions and partnerships to bolster its capabilities and expand into new markets, including pharmaceuticals and environmental monitoring [15][32].

Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook on its future performance [3]. Core Viewpoints - The company is positioned as a "small giant" in the scientific instruments sector, with a comprehensive product lineup and a strong focus on domestic market growth, particularly in chromatography instruments [1][3]. - The company has shown significant recovery in its performance, with a notable year-on-year revenue growth of 38% in Q1 2025, and a projected revenue increase to 3.1 billion yuan in 2024 [1][3]. - The report highlights the potential for domestic substitution in the chromatography market, with the market size expected to grow from 9.2 billion yuan in 2019 to approximately 16 billion yuan by 2024, reflecting a compound annual growth rate of about 11.7% [2][3]. Summary by Sections 1. Company Overview - Established in 2006, the company focuses on scientific instruments, developing a full range of products including organic element analysis, sample preparation, chromatography, and general instruments [1][14]. - The company has achieved high levels of product localization and profitability, reducing reliance on upstream supply chains [1]. 2. Market Position - The company leads in the organic element analysis sector, with successful products like the Kjeldahl nitrogen analyzer and Dumas nitrogen analyzer, securing contracts with major clients [1][2]. - In the sample preparation segment, the company has seen substantial sales growth, particularly in the lithium battery and petrochemical sectors [1]. 3. Chromatography Market Potential - The chromatography market is expanding rapidly, with liquid chromatography instruments capturing 38% of the market share in early 2025, followed closely by gas chromatography at 35% [2]. - The company is actively developing its "Wukong" high-efficiency liquid chromatography and "GAS" gas chromatography-ion mobility spectrometry instruments, which are gaining acceptance in various industries [2][3]. 4. Financial Projections - The company is expected to achieve revenues of 3.7 billion yuan in 2025, with a net profit of 500 million yuan, and projected earnings per share (EPS) of 0.54 yuan [3][4]. - The report anticipates a steady increase in revenue and profit margins, with a projected net profit growth rate of 253.2% in 2025 [4]. 5. Competitive Advantages - The company has established a strong R&D foundation, with a significant number of patents and ongoing projects that align with national standards [22][26]. - The strategic acquisitions and partnerships have enhanced the company's capabilities and market reach, positioning it well for future growth [15][32].

证券代码：430476 证券简称：海能技术 公告编号：2025-071 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、基本情况 海能未来技术集团股份有限公司（以下简称"公司"）分别于 2025 年 4 月 27 日、2025 年 5 月 20 日召开第五届董事会第六次会议、2024 年年度股东会， 审议通过了《关于变更注册资本及修订<公司章程>的议案》，具体内容详见公司 在北京证券交易所信息披露平台（www.bse.cn）上披露的《第五届董事会第六次 会议决议公告》（公告编号：2025-030）、《关于拟修订<公司章程>公告》（公告编 号：2025-055）、《2024 年年度股东会决议公告》（公告编号：2025-063）。 二、变更登记与备案情况 公司已经完成上述工商变更登记及公司章程备案工作，并于 2025 年 6 月 6 日取得济南高新技术产业开发区管理委员会换发的《营业执照》。本次工商变更 完成后，公司注册资本由"捌仟肆佰伍拾柒万玖仟捌佰元整"变更为"捌仟伍佰 壹拾柒万玖仟捌佰元整"，除上 ...

证券代码：430476 证券简称：海能技术 公告编号：2025-070 海能未来技术集团股份有限公司 回购进展情况公告 一、 回购方案基本情况 (一)审议及表决情况 海能未来技术集团股份有限公司（以下简称"公司"）于 2025 年 3 月 20 日召开了 第五届董事会第五次临时会议、第五届监事会第三次临时会议，审议通过了《关于以集 中竞价交易方式回购公司股份方案的议案》。 (二)回购用途及目的 基于对公司未来发展的信心及公司价值的认可，为维护广大投资者的利益，增强投 资者信心，推进股票价值与公司内在价值相匹配，提升公司股票长期投资价值，公司积 极响应党中央、国务院决策部署，根据中国人民银行、金融监管总局、中国证监会《关 于设立股票回购增持再贷款有关事宜的通知》，公司决定以自有资金及银行提供的股票 回购专项贷款资金回购公司股份。 本次回购的股份将用于实施股权激励，以引进和稳定优秀经营管理人才，提升经营 管理团队的凝聚力，推进长期激励与约束机制，使各方共同关注公司的长远发展，确保 公司发展战略和经营目标的实现，提升公司整体价值。 (三)回购方式 本次回购方式为竞价方式回购。 (四)回购价格 本次回购价格不超过 1 ...

Core Insights - The innovative drug sector is experiencing strong performance driven by multiple catalysts, including the approval of 11 innovative drugs by the National Medical Products Administration, showcasing the commercialization potential of pharmaceutical companies [4] - China's pharmaceutical companies are achieving breakthroughs through technological innovation and international expansion, with a significant increase in the number of innovative drugs under development, reaching 4,804 by 2024, making China the second globally after the US [4] - The government is providing comprehensive support for innovative drugs, with policies aimed at enhancing the entire value chain from research and development to payment, which is expected to improve the commercialization process for innovative drugs [4] Industry Analysis - The demand for innovative drugs is driven by an aging population and unmet medical needs in areas such as cancer and autoimmune diseases, with the elderly population expected to reach 310 million by the end of 2024, accounting for 22% of the total population [4] - The penetration rate of innovative drugs for autoimmune diseases remains low, indicating substantial market demand [4] Company-Specific Insights - **NuoSiLanDe**: An innovative biotech company with its first gene therapy drug expected to be approved by 2025, targeting new pathways and preparing for commercialization [4][5] - **KangLeWeiShi**: Focused on HPV vaccines, with significant progress in its pipeline, including a three-valent HPV vaccine expected to be approved by 2025 [4] - **DeYuan Pharmaceutical**: Specializes in chronic disease markets, with a focus on diabetes and cardiovascular diseases, and is developing a first-class innovative drug in collaboration with WuXi AppTec [4][5] - **JinBo Bio**: Leading in recombinant collagen technology with applications in skincare and medical fields, collaborating with various research institutions to advance its product offerings [7] - **HaiNeng Technology**: Aiming to replace imported scientific instruments, particularly in the chromatography sector, with plans to launch a new chromatography workstation software by 2025 [7] - **XinZhi Bio**: Focused on life science instruments, with a strategy to streamline its product offerings and enhance application scenarios [7] - **FeiYi Pharmaceutical**: Engaged in CDMO business, providing services to major pharmaceutical companies in Japan and South Korea, with plans to expand into cardiovascular drug production [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][4] Core Views - The company is expected to see revenue growth driven by downstream expansion and the chromatography and spectroscopy series, with a projected revenue increase of 38% year-on-year in Q1 2025 [2][4] - Despite a decline in 2024 revenue and net profit, the outlook for Q1 2025 is positive, indicating a recovery trend [4] - The company is actively developing new scientific instruments that are expected to lead the industry, and there is a strong push for domestic substitution [4] Financial Summary - In 2024, the company achieved revenue of 310 million yuan, a decrease of 9.06% year-on-year, with a net profit of 13.07 million yuan, down 70.99% [4][7] - For Q1 2025, revenue reached 55.50 million yuan, reflecting a year-on-year growth of 37.85, although the net profit was a loss of 0.52 million yuan [4][7] - The company’s revenue projections for 2025-2027 are 376 million yuan, 439 million yuan, and 504 million yuan respectively, with corresponding net profits of 47 million yuan, 53 million yuan, and 64 million yuan [4][7] Product Development and Market Expansion - The company has expanded its organic element analysis and sample pretreatment products into various sectors, including semiconductor materials, new energy materials, environmental pollution detection, and food safety [5] - The introduction of new products, such as the automatic dissolution apparatus, has led to significant sales growth, particularly in the pharmaceutical testing market [5] - The high-performance liquid chromatography products are expected to become a major revenue growth point as they reach domestic advanced levels and compete with international brands [5] Policy and Market Environment - Recent government policies encouraging large-scale equipment updates are expected to positively impact the company, particularly as universities and regulatory bodies begin to update their equipment [6] - The company is well-positioned to benefit from these developments, with ongoing projects in various sectors [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][4] Core Views - The company is expected to see revenue growth driven by downstream expansion and the chromatography and spectroscopy series, with a projected revenue increase of 38% year-on-year in Q1 2025 [2][4] - Despite a decline in 2024 revenue by 9% to 310 million yuan, the company anticipates a recovery with a revenue forecast of 376 million yuan in 2025, representing a 21.2% year-on-year growth [4][7] - The company has introduced several new scientific instruments that are expected to lead the industry, and it is actively pursuing domestic substitution efforts [4][5] Financial Summary - In 2024, the company reported a revenue of 310 million yuan, down 9.06% year-on-year, with a net profit of 13 million yuan, down 70.99% [4][10] - For Q1 2025, the company achieved a revenue of approximately 55.5 million yuan, marking a 37.85% increase year-on-year, although it reported a net loss of 0.52 million yuan [4][10] - The projected net profits for 2025, 2026, and 2027 are 47 million yuan, 53 million yuan, and 64 million yuan respectively, with corresponding EPS of 0.55, 0.62, and 0.75 yuan per share [4][7] Product Development and Market Expansion - The company has expanded its organic element analysis and sample pretreatment products into various sectors, including semiconductor materials, new energy materials, environmental pollution detection, and food safety testing [5][6] - The introduction of automatic dissolution testers and other pharmaceutical testing instruments has led to significant sales growth, with multiple procurement projects from provincial drug testing institutions and well-known pharmaceutical companies [5][6] - The company is increasing its market investment in high-performance liquid chromatography products, which are expected to become a significant revenue growth point in the future [5][6] Policy and Market Environment - Recent government policies encouraging large-scale equipment updates are expected to positively impact the company, particularly as universities and regulatory bodies begin updating their equipment [6][7] - The company is well-positioned to benefit from these developments, with ongoing support for domestic scientific instruments [6][7]

证券代码：430476 证券简称：海能技术 公告编号：2025-069 海能未来技术集团股份有限公司 关于 2020 年股票期权激励计划相关股票期权注销完成的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 海能未来技术集团股份有限公司（以下简称"公司"）于 2025 年 4 月 27 日 召开了第五届董事会第六次会议、第五届监事会第四次会议，审议通过了《关于 注销 2020 年股票期权激励计划第二个行权期相关股票期权的议案》。根据《上市 公司股权激励管理办法》、《北京证券交易所上市公司持续监管指引第 3 号——股 权激励和员工持股计划》、《海能未来技术集团股份有限公司 2020 年股票期权激 励计划》（以下简称"《2020 年股票期权激励计划》"）相关规定，公司向中国证 券登记结算有限责任公司北京分公司（以下简称"中国结算"）提交了注销股票 期权的申请，经中国结算审核确认，2020 年股票期权激励计划的相关股票期权 已注销完毕，现就相关情况公告如下： 一、 本次股票期权注销情况 1. 期权简称及代 ...

证券代码：430476 证券简称：海能技术 公告编号：2025-067 海能未来技术集团股份有限公司 2024 年年度权益分派实施公告 一、权益分派方案 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 海能未来技术集团股份有限公司 2024 年年度权益分派方案已获 2025 年 5 月 20 日召开的股东会审议通过，本次实施分配方案距离股东会审议通过的时间 未超过两个月。 现将权益分派事宜公告如下： 本次权益分派基准日合并报表归属于母公司的未分配利润为 195,904,438.08 元，母公司未分配利润为 230,250,664.97 元。本次权益分派共计派发现金红利 12,167,865 元。 见公司 2025 年 4 月 28 日在北京证券交易所信息披露平台(www.bse.cn)上披露的 1、本公司 2024 年年度权益分派方案为： 以公司股权登记日应分配股数 81,119,100 股为基数（应分配总股数等于股权 登记日总股本 85,179,800 股减去回购的股份 4,060,700 股，根据《 ...